Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, The major objective of the global PPL is to guide the prioritization of incentives and funding, help align R&D priorities with public health needs and support global coordination in the fight against antibioticresistant bacteria. The WHO PPL targets policy initiatives to incentivize basic science and advanced R&D by both public funding agencies and the private sector investing in new antibiotics. 
SELECTION OF ANTIBIOTIC-RESISTANT BACTERIA TO BE PRIORITIZED
Twenty bacteria were selected in line with current burden of diseases and previous prioritization exercises. Since the focus of this prioritization exercise was R&D for new antibiotics, it did not address prioritization for mycobacteria, fungi, protozoa, helminthes and viruses, which therefore were not considered for inclusion.
SELECTION OF CRITERIA FOR PRIORITIZATION
The following ten criteria were selected by the coordinating group of experts on the basis of their experience and previous prioritization exercises, reflecting the principles of MCDA (completeness, nonredundancy, non-overlap and preference independence): all-cause mortality, healthcare and community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in hospital and community settings, treatability and current pipeline. For each criterion estimates based on best available evidence were summarised to inform each pairwise comparison.
DATA EXTRACTION AND SYNTHESIS
Evidence for each criterion was extracted from multiple sources, including: databases of European- 
FINALIZATION OF THE RANKING OF PATHOGENS
The PPL was reviewed by the coordinating group and the advisory board in collaboration with WHO during a meeting held in Geneva 25-27 January 2017. The advisory board was composed of eight experts in the field not involved in the first two steps to act as a panel of external experts. The methodology used for the prioritization of pathogens showed a high stability of the list. No changes in the ranking were noted after stratifying the experts according to their background and geographical origin. A sensitivity analysis was performed, excluding the experts who were less consistent with their preferences with no major changes in the list. The results of the MCDA ranking and the sensitivity analysis were compared during the meeting; all differences between the lists were discussed and adjudicated.
The experts agreed on clustering the pathogens according to the type of resistance and then stratifying the results in three priority tiers: critical, high and medium. 
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STRENGTHS AND LIMITATIONS OF THE GLOBAL PPL
 The MCDA methodology used to develop the global PPL showed high stability of the final ranking and can be easily adopted for regular updates of the priority list or when new evidence appears or new resistance threats are identified.
 The panel found significant limitations of the current evidence for infections due to antibiotic-resistant bacteria in community and healthcare settings, in particular with respect to the frequency and burden of infections. High-quality data are missing, especially for community-acquired infections and from low-income countries.
 The panel underlines the lack of surveillance data on livestock and food, highlighting the need for coordination between human and animal surveillance systems. Inaccurate or incomplete surveillance data delay translational research on the antibiotic resistance threat and reduce the effectiveness of the "One Health" approach to limit the spread of resistance.
